BR122019018186B8 - cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica - Google Patents

cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Info

Publication number
BR122019018186B8
BR122019018186B8 BR122019018186A BR122019018186A BR122019018186B8 BR 122019018186 B8 BR122019018186 B8 BR 122019018186B8 BR 122019018186 A BR122019018186 A BR 122019018186A BR 122019018186 A BR122019018186 A BR 122019018186A BR 122019018186 B8 BR122019018186 B8 BR 122019018186B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
dotap chloride
enantiomerically pure
chloride
dotap
Prior art date
Application number
BR122019018186A
Other languages
English (en)
Other versions
BR122019018186B1 (pt
Inventor
Hedinger Alfred
Platscher Michael
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschraenkter Haftung filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of BR122019018186B1 publication Critical patent/BR122019018186B1/pt
Publication of BR122019018186B8 publication Critical patent/BR122019018186B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção se refere a cloreto de dotap puro em termos enantioméricos e modificações cristalinas estáveis de cloreto de (2r,s)-, (2s)- e (2r)-dotap, um processo para a preparação destas modificações, e o uso deles como um constituinte para a preparação de medicamentos.
BR122019018186A 2004-11-26 2005-11-07 cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica BR122019018186B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
DE102004057303.4 2004-11-26
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid
BRPI0518489A BRPI0518489B8 (pt) 2004-11-26 2005-11-07 cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Publications (2)

Publication Number Publication Date
BR122019018186B1 BR122019018186B1 (pt) 2021-03-09
BR122019018186B8 true BR122019018186B8 (pt) 2021-07-27

Family

ID=35789283

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0518489A BRPI0518489B8 (pt) 2004-11-26 2005-11-07 cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica
BR122019018186A BR122019018186B8 (pt) 2004-11-26 2005-11-07 cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0518489A BRPI0518489B8 (pt) 2004-11-26 2005-11-07 cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica

Country Status (21)

Country Link
US (2) US8853283B2 (pt)
EP (1) EP1814843B1 (pt)
JP (1) JP4880612B2 (pt)
KR (1) KR101249370B1 (pt)
CN (2) CN101065350A (pt)
AU (1) AU2005309107B2 (pt)
BR (2) BRPI0518489B8 (pt)
CA (1) CA2589218C (pt)
DE (1) DE102004057303A1 (pt)
ES (1) ES2545906T3 (pt)
HK (1) HK1178143A1 (pt)
HU (1) HUE027554T2 (pt)
IL (1) IL183324A (pt)
MX (1) MX2007006128A (pt)
NO (1) NO338885B1 (pt)
NZ (2) NZ582382A (pt)
PL (1) PL1814843T3 (pt)
PT (1) PT1814843E (pt)
RU (1) RU2463291C2 (pt)
WO (1) WO2006056312A1 (pt)
ZA (1) ZA200705169B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2721366C (en) * 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
BR112013029588B1 (pt) * 2011-05-20 2021-10-26 Merck Patent Gmbh Processo para preparação de uma forma cristalina de cloreto de (2r,s)-, (2s)- ou (2r)- dotap, e composição farmacêutica
SI3892295T1 (sl) 2011-05-24 2023-09-29 BioNTech SE Individualizirana cepiva proti raku
ES2689799T3 (es) * 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
EA003130B1 (ru) * 1996-05-08 2003-02-27 Ника Хелт Продактс Лимитед Катионные виросомы в качестве системы для переноса генетического материала
EP0938298B1 (en) * 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) * 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) * 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
CN101065350A (zh) 2007-10-31
WO2006056312A1 (de) 2006-06-01
IL183324A0 (en) 2007-09-20
EP1814843A1 (de) 2007-08-08
NZ582382A (en) 2010-08-27
AU2005309107B2 (en) 2011-07-21
BRPI0518489A2 (pt) 2008-11-25
ES2545906T3 (es) 2015-09-16
NO20073286L (no) 2007-06-25
ZA200705169B (en) 2008-08-27
CA2589218A1 (en) 2006-06-01
BRPI0518489B8 (pt) 2021-05-25
PL1814843T3 (pl) 2015-11-30
EP1814843B1 (de) 2015-06-24
CN102796016A (zh) 2012-11-28
KR101249370B1 (ko) 2013-04-01
HUE027554T2 (en) 2016-10-28
IL183324A (en) 2013-10-31
MX2007006128A (es) 2007-07-13
JP4880612B2 (ja) 2012-02-22
DE102004057303A1 (de) 2006-06-01
AU2005309107A1 (en) 2006-06-01
US8853283B2 (en) 2014-10-07
RU2007123673A (ru) 2009-01-10
BR122019018186B1 (pt) 2021-03-09
KR20070084501A (ko) 2007-08-24
NZ556060A (en) 2010-03-26
JP2008521757A (ja) 2008-06-26
CA2589218C (en) 2013-12-17
CN102796016B (zh) 2015-09-02
US9457087B2 (en) 2016-10-04
US20140370081A1 (en) 2014-12-18
PT1814843E (pt) 2015-10-13
BRPI0518489B1 (pt) 2020-03-31
HK1178143A1 (zh) 2013-09-06
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
US20080014254A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
BR122019018186B8 (pt) cloreto de (2s)-dotap enantiomericamente puro, seu uso, e composição farmacêutica
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
CL2007003326A1 (es) Compuestos derivados de pirrol[2,3-b]piridina, moduladores de la actividad del c-fms y/o el c-kit; composicion farmaceutica; y uso para el tratamiento de tumores de celulas mamarias, asma, artritis reumatoide, enfermedad de parkinson, entre otras.
BRPI0519474A2 (pt) derivados de quinazolina para inibir o crescimento de cÉlulas cancerosas e mÉtodo para a preparaÇço destes
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
EA200901319A1 (ru) Композиции для назального введения
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BR0207726A (pt) Sais farmacêuticos
EA200870599A1 (ru) Стабильные препараты лаквинимода
TW200716628A (en) Novel compounds
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
WO2007093624A3 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EA200702253A1 (ru) Фармацевтическая композиция
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
ECSP099426A (es) Compuestos de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7il para la modulación de la actividad del adrenoreceptor beta2
MX2010001574A (es) Ligandos del receptor cannabinoide.
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
BRPI1007350B8 (pt) compostos espiro heterocíclicos bicíclicos
EA201170512A1 (ru) Композиция для перорального введения
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO